
    
      Primary Objective of the Study: To demonstrate that the efficacy of peginterferon alfa-2a
      40KD combination therapy with ribavirin in interferon na√Øve patients with chronic hepatitis C
      (CHC) virus infection genotype 2 or 3 given for 12 weeks is non-inferior to 24 weeks.
    
  